Asian-Pacific consensus statement on the management of chronic hepatitis B

A 2008 update

Yun Fan Liaw, Nancy Leung, Jia Horng Kao, Teerha Piratvisuth, Edward Gane, KwangHyub Han, Richard Guan, George K.K. Lau, Stephen Locarnini

Research output: Contribution to journalReview article

772 Citations (Scopus)

Abstract

Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.

Original languageEnglish
Pages (from-to)263-283
Number of pages21
JournalHepatology International
Volume2
Issue number3
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Virus Diseases
Drug Therapy
Viral Drug Resistance
Guidelines
Therapeutics
Liver
Natural History
Alanine Transaminase
Drug Resistance
Liver Transplantation
Interferons
Genotype
Biopsy
Mutation
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Liaw, Yun Fan ; Leung, Nancy ; Kao, Jia Horng ; Piratvisuth, Teerha ; Gane, Edward ; Han, KwangHyub ; Guan, Richard ; Lau, George K.K. ; Locarnini, Stephen. / Asian-Pacific consensus statement on the management of chronic hepatitis B : A 2008 update. In: Hepatology International. 2008 ; Vol. 2, No. 3. pp. 263-283.
@article{f75e56cc79e54d8180ff16ea2b09694e,
title = "Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update",
abstract = "Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier {"}Asian-Pacific consensus statement on the management of chronic hepatitis B{"} was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.",
author = "Liaw, {Yun Fan} and Nancy Leung and Kao, {Jia Horng} and Teerha Piratvisuth and Edward Gane and KwangHyub Han and Richard Guan and Lau, {George K.K.} and Stephen Locarnini",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s12072-008-9080-3",
language = "English",
volume = "2",
pages = "263--283",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

Liaw, YF, Leung, N, Kao, JH, Piratvisuth, T, Gane, E, Han, K, Guan, R, Lau, GKK & Locarnini, S 2008, 'Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update', Hepatology International, vol. 2, no. 3, pp. 263-283. https://doi.org/10.1007/s12072-008-9080-3

Asian-Pacific consensus statement on the management of chronic hepatitis B : A 2008 update. / Liaw, Yun Fan; Leung, Nancy; Kao, Jia Horng; Piratvisuth, Teerha; Gane, Edward; Han, KwangHyub; Guan, Richard; Lau, George K.K.; Locarnini, Stephen.

In: Hepatology International, Vol. 2, No. 3, 01.01.2008, p. 263-283.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Asian-Pacific consensus statement on the management of chronic hepatitis B

T2 - A 2008 update

AU - Liaw, Yun Fan

AU - Leung, Nancy

AU - Kao, Jia Horng

AU - Piratvisuth, Teerha

AU - Gane, Edward

AU - Han, KwangHyub

AU - Guan, Richard

AU - Lau, George K.K.

AU - Locarnini, Stephen

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.

AB - Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.

UR - http://www.scopus.com/inward/record.url?scp=51049107683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049107683&partnerID=8YFLogxK

U2 - 10.1007/s12072-008-9080-3

DO - 10.1007/s12072-008-9080-3

M3 - Review article

VL - 2

SP - 263

EP - 283

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -